Rocket Pharmaceuticals, Inc. Warrant (RCKTW) Stock Price
RCKTWStock
$0.00
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta3.09
RCKTW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-106.97%
Price vs S&P 500 (4W)-72.75%
VGM Score12.03
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RCKTWRocket Pharmaceuticals, Inc. Warrant | — | — | F | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Rocket Pharmaceuticals, Inc. Warrant
Rocket Pharmaceuticals is a late-stage biopharmaceutical company developing gene therapies for rare pediatric diseases. Its pipeline includes five clinical and preclinical programs targeting Fanconi Anemia, Leukocyte Adhesion Deficiency, Pyruvate Kinase Deficiency, Danaon Disease, and Infantile Malignant Osteopetrosis. The company focuses on research, development, and commercialization of its gene therapy candidates.